Journal
CLINICA CHIMICA ACTA
Volume 491, Issue -, Pages 81-84Publisher
ELSEVIER
DOI: 10.1016/j.cca.2019.01.019
Keywords
Alzheimer; Psychiatric disorders; CSF; Tau; Amyloid; Neurofilaments; Glia; YKL-40
Categories
Funding
- Ilidio Pinho professorship, at the University of Aveiro, Portugal
- iBiMED at the University of Aveiro, Portugal [UID/BIM/04501/2013]
Ask authors/readers for more resources
Psychiatric disorders are currently classified, in the majority of cases, by clinical syndromes. However, advances over the last decade in imaging and biochemical biomarkers in several Central Nervous System (CNS) disorders anticipate the incorporation of some of these markers in the diagnostic work-up of psychiatric conditions. In particular, CSF biomarkers offer the possibility of detecting a wide range of pathophysiological processes in the CNS. Newer CSF markers can measure axonal and synaptic damage, glial activation, and oxidative stress in CNS disorders with high precision. The possibility that these markers can be applied in the differential diagnosis of common psychiatric disorders such as Schizophrenia, Major Depressive or Bipolar Disorders not only to rule out neurodegenerative diseases but also to identify specific biomarker signatures has yet to be explored. In particular, synaptic proteins in CSF could be useful as markers of synaptic and neurotransmitter transmission impairment since these are key molecular features of psychiatric conditions. In this paper we outline the current and potential applications of CSF biomarkers in psychiatric disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available